Our Mission is to improve the quality of life for hemodialysis patients by introducing healthier vascular access systems.

With over 2 million people around the world currently suffering from End Stage Renal Disease – defined as that level of kidney failure when kidney dialysis (hemodialysis) becomes mandatory or a transplant is required – the need for simple, reliable, and long lasting access to a patient’s blood stream has never been greater.

Given the serious complications – infection, thrombosis, and cost – associated with existing methods of hemodialysis vascular access, The Circuport™ System with its revolutionary simplicity of design has the potential to offer patients a new lease on life.

The Circuport™ System provides a new direction in dialysis through a new mode of access that works with the natural flow of blood in the body.

**This is an investigational device and is not for sale in the United States.**

Product

The Circuport™ System features an implantable port for direct access to the vessel, and a frame that prevents the compression of blood vessels during access with the specially designed dialysis needle.

Two such ports are implanted in each patient. One port is sutured to an artery, and the other to a vein. An anti-compression frame is assembled around each port and vessel and completely covered by the skin. The final assembly provides direct, sterile, durable and quick access into the patient’s blood stream.

Unlike existing systems, the artery and vein to be used for The Circuport™ System do not need to be in close proximity to each other. This not only presents many new possibilities for patients who have run out of suitable sites for current access systems, but is also expected to improve the efficiency of the hemodialysis process by eliminating blood admixture (the mingling of filtered and unfiltered blood) that can occur when the blood is removed from and returned to sites that are very close to each other in the same blood vessel, prevents squeezing the artery or vein during the insertion of the needle. As an added safeguard, the specialized needles allow the healthcare practitioner to insert the needle to the appropriate safe depth every time.

Perhaps most importantly, The Circuport™ System prevents the inevitable damage to the blood vessel wall which results from puncturing an artery or a vein with a sharp needle, several times a week.

By providing a sturdy access point, made of silicone which is protected with a titanium casing, the potential for damage to the arterial wall during the process of needle puncture is greatly reduced.

This critical part of the Circuport™ port has demonstrated durability equivalent to two years of hemodialysis.

The Circuport™ System is easy to implant using common vascular surgical techniques and is no harder to implant than existing access systems. It is expected that a vascular surgeon will be able to implant a pair of ports in approximately an hour. The ports have been designed to last for two years for a typical dialysis patient receiving treatment three times per week.

While the core part of the port prevents damage to the arterial wall, since the needle never penetrates the artery or the PTFE patch, the anti-compression frame prevents squeezing the artery or vein during the insertion of the needle. As an added safeguard, the specialized needles allow the healthcare practitioner to insert the needle to the appropriate safe depth every time.

The Circuport™ System is designed to provide a new direction for dialysis with the goal of reducing the risks of arterial damage, cardiac overload, vessel thrombosis and infection.

System

Usage

**This is an investigational device and is not for sale in the United States.**

About Us

Circuport, Inc, was founded by two prominent vascular surgeons, Dr. John Edoga and Dr. Thierry Richard.

Dr. John Edoga

Dr. Thierry Richard

Over the past ten years, they have developed The Circuport System based on their several decades of collective practical experience with hemodialysis patients, and as a result of their dissatisfaction with the existing access systems for such patients.

Scientific Advisory Board

Todd S. Ing

For 25 years, Todd Ing worked as a Nephrologist at the Hines VA Hospital and as a Professor of Medicine at the Stritch School of Medicine, Loyola University Chicago.

A dialysis enthusiast, he has written about many aspects of dialysis.

He is the Founding President of the International Society for Hemodialysis and an Editor of the Handbook of Dialysis.

He has received the Medal of Excellence from the American Association of Kidney Patients and the National Torchbearer Award from the American Kidney Fund.

Carl Kjellstrand

Carl Kjellstrand received his Nephrology training at University of Lund with Nils Alwall 1957 – 1964. He has published over 500 papers, edited 21 books or symposia publications and 386 abstracts of which 287 were selected for presentation. He has also been Professor of Medicine and Surgery at University of Minnesota, and Professor of Medicine and Bioethics at University of Alberta, Canada.

Presently, Kjellstrand is the Adjunct Professor of Medicine, State University of New York at Brooklyn, the Clinical Professor of Medicine at Loyola University, Chicago, and Docent at Karolinska Institute in Stockholm. Additionally, he is an Honorary Member of The Peruvian Society of Pediatrics and Nephrology and the Venezuelan Society of Nephrology. He is a Fellow of the American College of Physicians and the Royal College of Physicians and Surgeons, Canada and is also a Life Member of the Asian Pacific Society of Nephrology.

Carl Kjellstrand was listed among the “Best Physicians in the USA in 1982, 1984, and 1992 – 1995. He was President of the American Society for Artificial Organs, Vice President of the International Society for Artificial Organs, President of the Canadian Society of Nephrology and President of the Canadian Organ Replacement Registry.

He has been a member of numerous international, federal and state committees devoted to dialysis and transplantation.

Kjellstrand has been invited to lecture at over 200 national and international meetings and has been a Visiting Professor / Lecturer at approximately 200 academic institutions.

Michael Resnikoff

Michael Resnikoff is a practicing vascular surgeon with 15 years of clinical experience. He is a graduate of the University of Pennsylvania Medical College, was trained at the prestigious Albany Medical Center and is certified by the American Boards of General and Vascular Surgery. Dr Resnikoff is currently in practice at Morristown Medical Center (an affiliate of the Mount Sinai School of Medicine) . He focuses on all aspects of surgical and endovascular treatment of vascular disease.

At Morristown, he is active in resident training. Additionally, he has been chief of the Vascular Section of the Department of Surgery, and has received Top Doctor recognition in the state of New Jersey.

Dr Resnikoff and his partners have actively participated in several FDA sponsored trials. By so doing, they can offer their patients the opportunity to enroll in and benefit from the most current clinical vascular and endovascular treatments.

Michael has particular expertise in dialysis access procedures. Dr. Resnikoff and his group have been recognized by the Transatlantic Renal Council as premier hemodialysis access experts. Dr. Resnikoff strives to create the ideal access for all of his dialysis patients, has had hands-on experience in the pre-clinical implantation and application of the Circuport Vascular Access System and is a co-inventor of the Circuport specialized Needle system.